Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17026525 | 0.88 | CA12 (0.49) | NOS1METAP2CA12CA1CA9 | |
| SCHEMBL31436559 | 0.88 | CA12 (0.49) | NOS1METAP2CA12CA1CA9 | |
| SCHEMBL27849485 | 0.81 | ROCK1 (0.41) | NOS1METAP2CSNK2A1ROCK1ROCK2 | |
| SCHEMBL31558305 | 0.79 | INSR (0.39) | CA12CA1CA9ROCK1ROCK2 | |
| SCHEMBL4569255 | 0.79 | NOS1 (0.49) | NOS1METAP2CSNK2A1ROCK1ROCK2 | |
| SCHEMBL1141784 | 0.76 | RAB9A (0.57) | NOS1METAP2CSNK2A1ROCK1ROCK2 | |
| SCHEMBL28989870 | 0.76 | CA12 (0.39) | CA12CA1CA9AXL | |
| SCHEMBL1274214 | 0.76 | CA12 (0.49) | CA12CA1CA9MEN1GAA | |
| SCHEMBL31327356 | 0.75 | AXL (0.46) | NOS1METAP2CSNK2A1RAB9AMAPT | |
| SCHEMBL25097633 | 0.75 | NOS1 (0.45) | NOS1METAP2CSNK2A1ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| EP-4146658-B1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PREC MEDICINE OPM (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-12441707-B2 | Indazole compounds | TYRA BIOSCIENCES, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250248998-A1 | LRRK2 Inhibitors | Brenig Therapeutics, Inc. | 2025-08-07 | — | — | US | disclosed |
| CN-115697990-B | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120004858-A | Fibroblast growth factor receptor inhibitor, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2025061029-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | WO | disclosed |
| EP-4504722-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119306723-A | Indazole FGFR2/3 selective inhibitor, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-8268869-B2 | Vinyl indazolyl compounds | ELI LILLY AND COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012047699-A1 | CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR | ELI LILLY AND COMPANY (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120083511-A1 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL | ELI LILLY AND COMPANY (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2427449-A1 | VINYL INDAZOLYL COMPOUNDS | Eli Lilly and Company (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| WO-2010129509-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286209-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248998-A1 | LRRK2 Inhibitors | LRRK2, PARK7, PINK1 | NOS1 3610/4885METAP2 3077/4885CSNK2A1 111/4885 |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | NOS1 4630/4885METAP2 2195/4885CSNK2A1 118/4885 |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | NOS1 1180/4885METAP2 3803/4885CSNK2A1 112/4885 |
| US-20120083511-A1 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL | ADH1A, ADH1C, ADH5 | NOS1 4439/4885METAP2 4757/4885CSNK2A1 1321/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | NOS1 980/4885METAP2 4623/4885CSNK2A1 1583/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | NOS1 639/4885METAP2 1679/4885CSNK2A1 388/4885 |
| US-12441707-B2 | Indazole compounds | BRCA1, IDH2, TP53 | NOS1 1709/4885METAP2 2989/4885CSNK2A1 1300/4885 |
| US-20100286209-A1 | VINYL INDAZOLYL COMPOUNDS | VHL, IDH3B, IDH3A | NOS1 2893/4885METAP2 4541/4885CSNK2A1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.